CoChat
Sign Up
Cited by 49

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Diabetic dyslipidaemia

Soran, Handrean, Schofield, Jonathan D., Adam, Safwaan, Durrington, Paul N.·2016·Current Opinion in Lipidology
DOI 10.1097/mol.0000000000000318
Open this paper in CoChat — free account

Abstract

Purpose of review: The purpose is to discuss recent developments in the understanding of lipoprotein metabolism in diabetes, the cardiovascular risk associated with both type 1 and type 2 diabetes, recently published guidelines on the management of this risk, concerns over the use of statin treatment in diabetes, and other therapeutic options. Recent findings: Diabetic dyslipidaemia can be gross with massive hypertriglyceridemia, or subtle with a lipid profile which would be regarded as normal in a nondiabetic patient, but which hides underlying increases in atherogenic subfractions of LDL (e.g., small dense LDL, glycated LDL) and remnant lipoproteins. Statins can decrease these without the clinician being aware from routine biochemistry. In type 2 diabetes, HDL cholesterol levels are often reduced, whereas in type 1, insulin can raise HDL, but its antiatherogenic properties are compromised. Dyslipidaemia and hypertension predate the onset of glycaemia of diabetic proportions (metabolic syndrome). Obese people can thus die of diabetes before they develop it. Obesity should be prevented and treated. Statins decrease the risk of cardiovascular disease in diabetes or metabolic syndrome regardless of whether glycaemia worsens. Summary: One unassailable truth is that statin therapy is beneficial and should rarely, if ever, be withheld.

Overview

Integrity signals

Registry

Crossref · 10.1097/mol.0000000000000318

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 74

  1. Durrington, 2006, Diabetic dyslipidaemia, Diabetes: best practice & research compendium, 157
  2. Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 · DOI · Paper page
  3. 2005, JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice, Heart, 91, v1
  4. Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E · DOI · Paper page
  5. Kearney, 2008, Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X · DOI · Paper page
  6. Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 · DOI · Paper page
  7. Whiteley, 2005, Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey, Diabetes Care, 28, 1588, 10.2337/diacare.28.7.1588 · DOI
  8. Maahs, 2014, Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association, Circulation, 130, 1532, 10.1161/CIR.0000000000000094 · DOI
  9. Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
  10. Vazquez-Benitez, 2015, Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis, Diabetes Care, 38, 905, 10.2337/dc14-1877 · DOI
  11. Laing, 2003, Mortality from heart disease in a cohort of 23 000 patients with insulin-treated diabetes, Diabetologia, 46, 760, 10.1007/s00125-003-1116-6 · DOI · Paper page
  12. Laing, 2003, Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes, Stroke, 34, 418, 10.1161/01.STR.0000053843.03997.35 · DOI
  13. de Ferranti, 2014, Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association, Diabetes Care, 37, 2843, 10.2337/dc14-1720 · DOI
  14. Skrivarhaug, 2006, Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway, Diabetologia, 49, 298, 10.1007/s00125-005-0082-6 · DOI · Paper page
  15. Huxley, 2015, Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis, Lancet Diabetes Endocrinol, 3, 198, 10.1016/S2213-8587(14)70248-7 · DOI · Paper page
  16. Regensteiner, 2015, Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association, Circulation, 132, 2424, 10.1161/CIR.0000000000000343 · DOI · Paper page
  17. Johansen, 2016, Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes, Diabetologia, 59, 833, 10.1007/s00125-015-3856-5 · DOI
  18. Pencina, 2015, Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C, Eur J Prev Cardiol, 22, 1321, 10.1177/2047487315569411 · DOI · Paper page
  19. Soran, 2011, Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients, Ann Clin Biochem, 48, 566, 10.1258/acb.2011.010277 · DOI
  20. Liu, 2015, Association of high-density lipoprotein with development of metabolic syndrome components: a five-year follow-up in adults, BMC Public Health, 15, 412, 10.1186/s12889-015-1747-9 · DOI
  21. Griffin, 1994, Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk, Atherosclerosis, 106, 241, 10.1016/0021-9150(94)90129-5 · DOI · Paper page
  22. Rana, 2015, Metabolic dyslipidemia and risk of coronary heart disease in 28 318 adults with diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl, Am J Cardiol, 116, 1700, 10.1016/j.amjcard.2015.08.039 · DOI · Paper page
  23. Mackey, 2015, Lipoprotein particles and incident type 2 diabetes in the multiethnic study of atherosclerosis, Diabetes Care, 38, 628, 10.2337/dc14-0645 · DOI
  24. Ford, 2010, Prediabetes and the risk for cardiovascular disease: a systematic review of the evidence, J Am Coll Cardiol, 55, 1310, 10.1016/j.jacc.2009.10.060 · DOI · Paper page
  25. Younis, 2010, Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and nonstatin-treated type 2 diabetes, Diab Vasc Dis Res, 7, 289, 10.1177/1479164110383063 · DOI
  26. Younis, 2013, Small dense LDL is more susceptible to glycation than more buoyant LDL in type 2 diabetes, Clin Sci, 124, 343, 10.1042/CS20120304 · DOI
  27. Winocour, 1992, A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus, Diabetes Res Clin Pract, 18, 173, 10.1016/0168-8227(92)90143-F · DOI
  28. Winocour, 1986, Lipoprotein abnormalities in insulin-dependent diabetes mellitus, Lancet, 1, 1176, 10.1016/S0140-6736(86)91159-1 · DOI
  29. Durrington, 1982, Serum high density lipoprotein cholesterol subfractions in type I (insulin-dependent) diabetes mellitus, Clin Chim Acta, 120, 21, 10.1016/0009-8981(82)90073-0 · DOI
  30. Brethauer, 2014, Bariatric surgery improves the metabolic profile of morbidly obese patients with type 1 diabetes, Diabetes Care, 37, e51, 10.2337/dc13-1736 · DOI
  31. Purnell, 2013, The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study, Circulation, 127, 180, 10.1161/CIRCULATIONAHA.111.077487 · DOI · Paper page
  32. Cree-Green, 2015, Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes, Pediatr Diabetes
  33. Bagdade, 1991, Accelerated cholesteryl ester transfer in patients with insulin-dependent diabetes mellitus, Eur J Clin Invest, 21, 161, 10.1111/j.1365-2362.1991.tb01805.x · DOI
  34. Bhatnagar, 1996, Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with noninsulin-dependent diabetes mellitus, Diabet Med, 13, 139, 10.1002/(SICI)1096-9136(199602)13:2<139::AID-DIA15>3.0.CO;2-C · DOI
  35. Laffont, 2002, Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates, Biochim Biophys Acta, 1583, 99, 10.1016/S1388-1981(02)00188-9 · DOI
  36. Younis, 2012, HDL functionality in diabetes mellitus: potential importance of glycation, Clin Lipidol, 7, 561, 10.2217/clp.12.60 · DOI
  37. Saleheen, 2015, Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study, Lancet Diabetes Endocrinol, 3, 507, 10.1016/S2213-8587(15)00126-6 · DOI
  38. Soran, 2015, How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae, Curr Opin Lipidol, 26, 247, 10.1097/MOL.0000000000000194 · DOI
  39. Younis, 2013, High-density lipoprotein impedes glycation of low-density lipoprotein, Diab Vasc Dis Res, 10, 152, 10.1177/1479164112454309 · DOI
  40. Song, 2005, Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria, Diabetes Care, 28, 1718, 10.2337/diacare.28.7.1718 · DOI
  41. Hama, 2016, Changes in inflammation markers, adipose tissue properties, glucose homeostasis and lipoproteins after gastric bypass surgery in morbidly obese patients, Atherosclerosis, 231, e3, 10.1016/j.atherosclerosis.2013.07.016 · DOI
  42. Bays, 2016, Lipids and bariatric procedures part 1 of 2: scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT, J Clin Lipidol, 10, 33, 10.1016/j.jacl.2015.12.002 · DOI
  43. Aghamohammadzadeh, 2013, Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity, J Am Coll Cardiol, 62, 128, 10.1016/j.jacc.2013.04.027 · DOI
  44. Liu, 2016, Effect of bariatric surgery on HDL quantity and quality, Atherosclerosis, 245, e245, 10.1016/j.atherosclerosis.2015.10.031 · DOI
  45. Shimada, 2016, Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association, Lipids Health Dis, 15, 57, 10.1186/s12944-016-0223-6 · DOI
  46. Caslake, 2003, Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia, Atherosclerosis, 171, 245, 10.1016/j.atherosclerosis.2003.08.025 · DOI
  47. Younis, 2013, Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes, Clin Sci (Lond), 124, 343, 10.1042/CS20120304 · DOI
  48. Soran, 2015, Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment, Eur Heart J, 36, 2975
  49. Adhyaru, 2016, New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia, Endocrinol Metab Clin North Am, 45, 17, 10.1016/j.ecl.2015.09.002 · DOI
  50. Yang, 2015, A meta-analysis of the effects of statin treatment on cardiovascular events and all-cause mortality in diabetic dialysis patients, Int J Clin Exp Med, 8, 8415
  51. Rha, 2016, Impact of statin use on development of new-onset diabetes mellitus in Asian population, Am J Cardiol, 117, 382, 10.1016/j.amjcard.2015.11.009 · DOI
  52. Maki, 2014, An assessment by the Statin Diabetes Safety Task Force: 2014 update, J Clin Lipidol, 8, S17, 10.1016/j.jacl.2014.02.012 · DOI · Paper page
  53. Livingstone, 2016, Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS), Diabetologia, 59, 299, 10.1007/s00125-015-3802-6 · DOI
  54. Fuentes, 2015, Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study, Int J Cardiol, 201, 79, 10.1016/j.ijcard.2015.07.107 · DOI
  55. Garcia-Calvo, 2005, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1), Proc Natl Acad Sci U S A, 102, 8132, 10.1073/pnas.0500269102 · DOI · Paper page
  56. Bays, 2006, Lipid-lowering effects of colesevelam HCl in combination with ezetimibe, Curr Med Res Opin, 22, 2191, 10.1185/030079906X148436 · DOI
  57. Wierzbicki, 2010, Fibrates: no ACCORD on their use in the treatment of dyslipidaemia, Curr Opin Lipidol, 21, 352, 10.1097/MOL.0b013e32833c1e74 · DOI
  58. Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 · DOI · Paper page
  59. Keech, 2007, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, Lancet, 370, 1687, 10.1016/S0140-6736(07)61607-9 · DOI · Paper page
  60. Gerstein, 2013, Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial, Diabetes Care, 36, 1266, 10.2337/dc12-1311 · DOI
  61. Harris, 2008, Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives, Atherosclerosis, 197, 12, 10.1016/j.atherosclerosis.2007.11.008 · DOI · Paper page
  62. Seidah, 2013, Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies, Curr Pharm Des, 19, 3161, 10.2174/13816128113199990313 · DOI
  63. Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031 · DOI · Paper page
  64. Bays, 2015, Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial, J Clin Endocrinol Metab, 100, 3140, 10.1210/jc.2015-1520 · DOI
  65. Sattar, 2016, Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data, Lancet Diabetes Endocrinol, 4, 403, 10.1016/S2213-8587(16)00003-6 · DOI
  66. Jani, 2014, A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI), Diabetes Technol Ther, 16, 63, 10.1089/dia.2013.0253 · DOI
  67. Gutierrez, 2014, Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus, Arterioscler Thromb Vasc Biol, 34, 676, 10.1161/ATVBAHA.113.302677 · DOI
  68. Siahmansur, 2015, Unintended positive and negative effects of drugs on lipoproteins, Curr Opin Lipidol, 26, 325, 10.1097/MOL.0000000000000198 · DOI
  69. Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management, Lancet Diabetes Endocrinol, 2, 655, 10.1016/S2213-8587(13)70191-8 · DOI · Paper page
  70. Heaney, 1999, Prevention of recurrent pancreatitis in familial lipoprotein lipase deficiency with high-dose antioxidant therapy, J Clin Endocrinol Metab, 84, 1203, 10.1210/jcem.84.4.5617 · DOI
  71. Gaudet, 2014, Targeting APOC3 in the familial chylomicronemia syndrome, N Engl J Med, 371, 2200, 10.1056/NEJMoa1400284 · DOI · Paper page
  72. Burnett, 2009, Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency, Curr Opin Mol Ther, 11, 681
  73. Salmon, 2014, Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera(R)), Expert Rev Clin Pharmacol, 7, 53, 10.1586/17512433.2014.852065 · DOI
  74. Scott, 2015, Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency, Drugs, 75, 175, 10.1007/s40265-014-0339-9 · DOI

Cited by

Sorted by citations

Metadata

Authors
Soran, H., Schofield, J. D., Adam, S., & Durrington, P. N.
Affiliations
Cardiovascular Research Group, School of Biomedicine, University of Manchester
Venue
Current Opinion in Lipidology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-08
Volume
27
Issue
4
Pages
313-322
ISSN
  • 0957-9672
  • 1473-6535
DOI
10.1097/mol.0000000000000318
Cited by
49
References
16
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review